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Purpose of review: Glucocorticoids are frequently used in the treatment of patients with 
neurooncological disorders. This review addresses different clinical indications and provides 
information on beneficial and undesired effects exerted by these drugs. The most important 
cellular mechanisms of action of glucocorticoids under different conditions are highlighted.  
Recent findings: Glucocorticoids have been used for the treatment of lymphoid neoplasms for 
decades. In addition to pro-apoptotic effects, recent studies have delineated the induction of 
autophagy in lymphoma cells as an important alternative mode of cell death. In contrast, 
glucocorticoids may reduce the sensitivity of tumor cells, including glioma cells, other than 
lymphoma cells to chemotherapeutic agents. Corticosteroids also provide transient relief from 
neurological symptoms caused by increased intracranial pressure and edema associated with 
primary and secondary brain tumors. However, treatment with glucocorticoids is also 
commonly associated with considerable side effects including hyperglycemia, myopathy, 
osteoporosis, myopathy, lymphopenia and others.  
Summary: Although in clinical use for more than 40 years in the field of neurooncology, 
steroids remain a central and essential part in the treatment of brain tumor patients. Along 
with improved therapeutic options and prolonged life expectancy of many of these patients, 






Steroid hormones include the sex steroids such as androgens, estrogens and progestagens as 
well as the mineralocorticoids and glucocorticoids. The latter are referred to as “steroids” in 
clinical language use in oncology and have a multitude of functions that can be 
therapeutically exploited in tumor patients. Naturally occurring glucocorticoids in humans 
comprise cortisol (alternative name: hydrocortisone) and corticosterone which are produced 
by the adrenal gland. They are involved in various physiological conditions such as 
carbohydrate and protein catabolism, stress and immune responses and the regulation of 
inflammation and electrolyte levels in the blood [1].  
Glucocorticoids bind to the glucocorticoid receptor which is located in the cytoplasm. 
Subsequently, the receptor-ligand complex translocates into the nucleus where it binds to 
glucocorticoid response elements which are located in the promoter region of target genes. As 
a result, the expression of the affected gene is in most cases enhanced but negative 
transcriptional regulation is also possible [2].   
A plethora of synthetic glucocorticoids is available for therapeutic use. Compared to cortisol, 
they are characterized by different pharmacodynamic and pharmacokinetic properties. 
Dexamethasone is by far the most frequently used drug because of its low mineralocorticoid 
effects and long half-life. Together with other glucocorticoids it has been used in the field of 
neurooncology since the 1960’s [3]. 
 
Effects of glucocorticoids on lymphoma cells 
 
The induction of apoptotic cell death in lymphoid cells by glucocorticoids has been 
recognized several decades ago. This process comprises DNA fragmentation and appears to 
be independent of wild-type p53 activity [4-6]. Induction of apoptosis might be associated 
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with reduced transcriptional activity of nuclear factor of activated T cells (NFAT), the 
induction of glucocorticoid-induced leucine zipper (GILZ) and primarily dependent on the 
repressive function of the glucocorticoid receptor [7-9]. Furthermore, glucocorticoid-induced 
cell death may require the presence of glycogen synthase kinase (GSK)-3 [10, 11**]. More 
recent findings demonstrate the induction of autophagy, an alternative mode of cell death, in 
lymphoid cells as the main function of glucocorticoids [12]. This process involves the 
functional activity of Beclin-1, a key regulator protein in autophagy [13**]. Resistance to 
glucocorticoids partially results from mutations in the glucocorticoid receptor gene, deficient 
control of its expression or high levels of Bcl-2 [14, 15]. 
Because of their striking activity, glucocorticoids are commonly used in the treatment of 
lymphomatous lesions in the central nervous system (CNS). They have been included in 
almost all chemotherapy protocols for lymphoid malignancies but can also temporarily be 
administered alone. Dexamethasone, the standard drug, is generally applied in initial doses of 
4 to 16 mg per day. Because of unwanted side effects (see below), high doses should only be 
administered for a short period of time. Since lymphomatous neoplasms will respond rapidly 
to glucocorticoids and thus obscure a definitive diagnosis [16, 17], patients with suspicion of 
lymphoma should rather be treated with osmotic agents to reduce intracranial pressure until 
the diagnosis has been established [18]. Further, tumor remission in response to 
glucocorticoid administration is only temporary in most patients and must therefore be 
followed or accompanied by other chemotherapeutic agents.   
 
Effects of glucocorticoids on other tumor cells 
 
In CNS neoplasms other than lymphomas, the effects of glucocorticoids are much more 
controversial. Several in vitro studies suggest that dexamethasone and other steroids are 
inhibitors of cellular proliferation and may also induce cell death at high concentrations. 
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Administration of glucocorticoids to glioma-bearing animals was accompanied by prolonged 
survival in some reports [19-22]. In humans, only single reports have described tumor 
shrinkage in glioblastoma patients after dexamethasone treatment [23]. In contrast, a 
multitude of studies demonstrated that glucocorticoids lack any significant effect or even 
stimulate tumor cell growth in vitro and in vivo [24, 25]. Most importantly, glucocorticoids 
induce resistance to chemotherapeutic agents in various tumor models including gliomas [26-
28]. This effect may partially result from a dexamethasone-induced expression and increased 
activity of multidrug resistance transporters [29]. The reduced permeability of the blood-brain 
barrier for chemotherapeutic agents in response to glucocorticoids (see below) may also 
contribute to this phenomenon in vivo. Therefore, steroid administration should be minimized 
whenever possible prior to chemotherapy in brain tumor patients. Although critically followed 
in academic neurooncology, glucocorticosteroids are also criticized from the dietary 
standpoint in the alternative medical field because of their rapid induction of insuline 
secretion. There is a debate on carbohydrate-restricted diets which are of unproven relevance, 
but would need a rather restrictive approach to steroids [30].  
 
Effects of glucocorticoids on brain tumor-associated edema 
 
By far the most common indication for the administration of glucocorticoids to brain tumor 
patients is the need to reduce mass effect secondary to tumor-surrounding edema. This 
condition is frequently found in a variety of brain tumors, including gliomas, meningiomas 
and metastases and may be enhanced by cytotoxic therapy such as irradiation and 
chemotherapy. Treatment with glucocorticoids commonly results in a massive, albeit 
transient, improvement of the patient’s condition [31]. Small doses may be sufficient in many 
patients, e.g., 16 mg were not superior to 4 mg regarding improvement in Karnofsky 
performance status in a randomized trial in patients with brain metastases [32]. As with other 
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actions of glucocorticoids, the mechanisms that cause a reduction of tumor-associated edema 
are only partially understood. In preclinical animal studies, a reduction of the permeability of 
the capillary bed within the tumor was reported [33]. Here, the particular effect of steroids on 
the microvascular permeability of the brain may originate from differential signalling 
mechanisms in endothelial cells of the blood-brain barrier compared to other tissues [34].  
Several experimental in vivo models have demonstrated a favourable effect of glucocorticoids 
on glioma-associated edema [33, 35, 36]. Animal studies also revealed a dexamethasone-
induced expression of calcium-activated potassium channels and occludin which may be 
involved in the regulation of the blood-brain and blood-tumor barrier [37, 38*]. In vitro 
experiments demonstrated reduced vascular endothelial growth factor (VEGF) levels and 
increased expression of angiopoietin-1 and claudin-5 in response to corticosteroids [39, 40*]. 
In humans, the availability of brain imaging studies such as magnetic resonance imaging 
(MRI) and positron emission tomography (PET) has allowed for a better insight in the effects 
mediated by glucocorticoids on edema. These techniques revealed a decrease in peritumoral 
water content and reduced tumor capillary permeability after dexamethasone treatment [41-
44]. Tumoral perfusion, assessed by MRI, may also predict the imaging response response to 
glucocorticoids [45*].  
 
Guidelines for the management of brain tumor-associated edema: 
 
Glucocorticoids have been used for the treatment of tumor-associated edema for more than 40 
years. This is in sharp contrast to the very low number of clinical studies investigating these 
effects within randomized trials [32, 46]. However, about 70-100% of patients with intrinsic 
brain tumors or metastases are treated with steroids, either alone or during cytotoxic therapy 
[47]. Overall, a variety of individual therapy regimens in terms of dose and duration is used 
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[48]. Based on the existing literature, the following provides a clinical practice guideline [49, 
50]: 
In general, dexamethasone is considered the best available drug in order to provide temporary 
relief from symptoms that are due to an increase in intracranial pressure and edema. No 
general recommendation can be given for patients with asymptomatic brain tumors. In most 
cases, glucocorticoids can be withheld. Patients with mild symptoms caused by increased 
intracranial pressure and tumor-associeated edema will benefit from dexamethasone in a 
starting dose of 4-8 mg per day. Higher doses of dexamethasone such as 8-16 mg per day are 
indicated in patients suffering from more pronounced or even severe symptoms related to 
mass effect. A dose higher than 16 mg per day may be administered upon individual 
evaluation. However, additional benefit is only rarely observed in few patients based on the 
clinical experience of the authors and others [51]. It should be considered that phenytoin, a 
commonly used anticonvulsant, or many other CYP450 targets may reduce the bioavailability 
of dexamethasone and therefore require an adjustment of the dosage of the glucocorticoid [52, 
53]. 
No concluding guidelines can be given for the prophylactic use of steroids during 
radiotherapy of patients with primary or secondary brain tumors. Asymptomatic patients may 
remain free of glucocorticoids, and only a minority of the patients will require dexamethasone 
with doses ranging from 4-16 mg per day during irradiation. At present, corticosteroids are 
probably still overused in this indication and small doses may be sufficient in many patients 
[48, 54, 55*, 56]. Various heterogenous treatment schedules have been used. In general, 
because of its long half-life of 36-54 h, dexamethasone can be administered as a once-daily 
dosing in the morning [32, 54]. While steroids are required and effective during radiotherapy, 
they are probably ineffective in the management of delayed radiation-induced neurotoxicity 
[57]. The duration of glucocorticoid treatment should always be adapted to individual needs. 
Dose reductions should be considered after 7-10 days of administration [47, 54, 58].   
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Tapering and withdrawal 
 
There are no universally valid guidelines for the tapering of dexamethasone or other 
glucocorticoids. In most cases, a tapering schedule comprising 2 to 4 weeks might be 
appropriate but longer periods should be considered for patients who have been using steroids 
for several months [32, 47, 48]. 
Long-term administration of steroids, especially when given in high doses, goes along with 
secondary adrenal insufficiency. Prolonged intake of glucocorticoids can even lead to adrenal 
gland hypotrophy that may need a recovery period of several months after discontinuation of 
the exogenous glucocorticoid. 
Abrupt disruption or too rapid tapering of glucocorticoid therapy can be accompanied by a 
lack of endogenous corticosteroids. This is of particular importance in situations with 
increased glucocorticoid demand such as fever and physical stress. It may result in unspecific 
complaints such as nausea, headache, myalgias and symptoms of hypotension. In case of 
suspected hypocortisolism, the hormones of the hypothalamic-pituitary-adrenal axis can be 
assessed by laboratory tests. Slower tapering schedules will provide relief of symptoms in 
many patients. Manifest hypocortisolism should be substituted with hydrocortisone. Most 
patients require a dose in the range of 15-25 mg per day. In order to mimic the circadian 
cortisol secretion, one half to two thirds of the total daily dose should be administered in the 
morning [59, 60]. The exact dose must be individually adapted based on clinical symptoms 
and laboratory parameters such as electrolyte levels.  
 
Side effects of glucocorticoid therapy 
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Treatment with synthetic glucocorticoids is commonly associated with considerable undesired 
effects that can be linked to the physiological function of these hormones. While some effects 
are only observed after steroid intake for weeks or even months, other unwanted aspects of 
glucocorticoid treatment may become apparent within days. The following gives an overview 
on the most common and partially threatening side effects: 
 
Steroid-induced diabetes 
Glucocorticoids – as the name suggests – increase blood sugar levels by different mechanisms 
including the mobilization of glucose from the liver and the induction of gluconeogenesis. 
Elevated serum glucose levels are observed in up to 50% of patients receiving glucocorticoids 
[47]. Although many patients suffering from primary or secondary brain tumors face a limited 
life expectancy of few years or even less, the short- and long-term complications associated 
with diabetes must be taken in account. Furthermore, hyperglycemia may be associated with 
shorter survival in glioblastoma patients [61**]. Therefore, a regular determination of blood 
sugar levels is warranted and for patients with prolonged hyperglycemias a temporary 
therapeutic intervention (e.g. with insulin) should be established.  
 
Steroid myopathy 
Myopathy is commonly seen in patients taking glucocorticoids, especially after long-term 
therapy. It occurs in up to 50% of all patients requiring prolonged steroid use and is more 
commonly associated with the administration of fluorinated steroids [62, 63]. Clinical features 
include proximal and symmetrical muscle atrophy and weakness that may affect both upper 
and lower extremities. The underlying mechanisms have only been partially clarified but 
glucocorticoid-induced apoptosis in skeletal muscle cells may represent the most important 
cause [64, 65]. Myofibrillar protein degradation as a result of glucocorticoid-dependent 
stimulation of the proteasomal activity and suppression of insulin-like growth factor (IGF)-1 
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signalling in muscle cells may also contribute to muscle atrophy [66-68]. If prolonged 
treatment with glucocorticoids is indispensable, physical therapy is recommended in the 
absence of other available specific prevention measures [69]. 
 
Osteoporosis 
Long-term administration of glucocorticoids is frequently associated with osteoporosis which 
results in significant morbidity and mortality [70, 71]. The underlying pathophysiological 
mechanisms include the induction of apoptosis in osteoblasts and osteocytes [72] and a 
reduction of cytokine-dependent osteoblast differentiation [73**]. The effects of steroids on 
bone loss and increased fracture risk are dose-dependent. Particular attention should be paid 
to patients receiving other osteoporosis-promoting drugs such as loop diuretics or thyroxine. 
Special attention should also be given to individuals using medications that increase the risk 
of falling including antihypertensives, some anticonvulsants and benzodiazepines [74]. 
Bisphosphonates can be used for the prevention of fractures, especially in patients with longer 
life expectancy. These agents inhibit bone resorption by binding to bone mineral followed by 
a decreased activity of the osteoclasts. Teriparatide, a synthetic fragment of human 
parathyroid hormone, stimulates new bone formation and is available as a second-line option 
[75-77]. Patients receiving glucocorticoids should also be endowed with calcium (800-1200 
mg per day) and vitamin D supplements (> 800 IU per day) [78-80]. 
 
Other side effects: 
Treatment with glucocorticoids may affect electrolyte levels in the blood. Special attention 
must be given to decreased potassium levels that may reach life-threatening dimensions [81]. 
Timely oral substitution will prevent significant electrolyte disturbances in the majority of 
cases. Other side effects attributed to glucocorticoid therapy include psychiatric disorders 
such as anxiety, depressive disorders, insomnia and increased appetite. Administration of 
 11
glucocorticoids can also result in a marked suppression of the immune system leading to an 
increased risk for infections such as Pneumocystis jiroveci pneumonitis (PJP, formerly known 
as Pneumocystis carinii pneumonitis, PCP) [82, 83]. Despite the lack of general guidelines, it 
might be warranted that all patients receiving radio- and/or chemotherapy with concomitant 
steroid use and all patients with CTCAE grade 3 or 4 lymphopenia should obtain prophylactic 
treatment with trimethoprim-sulfamethoxazole or aerosolized pentamidine [69, 84, 85]. In 
order to avoid gastrointestinal side-effects due to peptic ulcers or even bleedings, the 
prophylactic administration of proton pump inhibitors, H2 blockers or antacids should be 
considered. Steroid cataract and peripheral edema have also been frequently reported in 
patients taking glucocorticoids [32, 47, 48, 58]. 
Unfortunately, no convincing alternative agents that might replace glucocorticoids are 
available. The phytotherapeutic agent H15 contains boswellic acids and may reduce tumor-
surrounding edema in the brain and therefore allow for a reduction of the steroid dose. 
However, it has only limited activity and has only been assessed in small clinical studies [86]. 
In modern neurooncology, anti-VEGF agents, such as bevacizumab, which is registered in the 
USA for recurrent glioblastoma [87**] and is in clinical trials for the newly diagnosed 
situation may - amongst a true anti-tumor effect, which is under debate - replace steroids 
when used for treatment. Animal experiments show that brain tumor-bearing mice survive 
longer because of the marked anti-edematous action of the VEGF receptor tyrosine kinase 
inhibitor cediranib, although the tumor cells proper are basically unaffected by the treatment 




The beneficial effects of corticosteroids on different pathological conditions place them in an 
outstanding position in the treatment of neurooncological patients. Most importantly, 
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glucocorticoids provide temporary relief from symptoms related to increased intracranial 
pressure and edema in consequence of primary and secondary brain tumors. They also remain 
a substantial part in the treatment of patients suffering from lymphoma manifestations in the 
CNS. Because of their side effects and multiple interactions with other treatment modalities, 
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